The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Neurocrine Biosciences, Inc.’s current trading price is -20.93% away from its 52-week high, while its distance from the 52-week low is 20.55%. The stock’s price range for this period has been between $103.63 and $157.98 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.2 million for the day, a number notably higher than the average daily volume of 0.94 million over the last three months.
Neurocrine Biosciences, Inc.’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $157.98 on 08/01/24 and a low of $103.63 for the same time frame on 11/10/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Neurocrine Biosciences, Inc. (NBIX) has experienced a quarterly decline of -18.43% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 12.61B and boasts a workforce of 1400 employees.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 132.02, with a change in price of -10.17. Similarly, Neurocrine Biosciences, Inc. recorded 871,319 in trading volume during the last 100 days, posting a change of -7.54%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for NBIX stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.10.
NBIX Stock Stochastic Average
Neurocrine Biosciences, Inc.’s raw stochastic average for the past 50 days is presently 31.54%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 68.19%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 60.90% and 57.38%, respectively.
NBIX Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -5.19%. However, over the past six months, we’ve seen a stronger performance of -12.66%. The price of NBIX fallen by 9.44% over the last 30 days. And in the last five days, it has surged by 8.55%.
